ライフサイエンスコーパス: MCS

1 MCS also yielded higher (P<0.05) d9 metabolite enrichmen

2 MCS and MRS only affected calcium solubility and dialysa

3 MCS approaches provide one of the most accurate similari

4 MCS centers have improved patient management by introduc

5 MCS has become the mainstream therapy for the end-stage

6 MCS may also be indicated in selected patients with refr

7 MCS may soon become the treatment option of choice in re

8 MCS medium exhibited higher sensitivity (95.6%; any cult

9 MCS recipients are debilitated and have some immunologic

10 MCSs predicted that our existing protocol would be subop

11 Five had positive flow crossmatches (78-192 MCS) with mean DSA of 55,869 SFI.

12 th DSA more than 10(5) and FCM more than 200 MCS are at higher risk for AMR.

13 ased on T-cell flow XMs (FXMs) less than 250 MCS and B-cell FXMs less than 300 mean channel shifts (M

14 Five had positive flow crossmatches (222-266 MCS) with mean DSA of 118,063 SFI.

15 pnea index score (46.4% versus 12.7%), SF-36 MCS score (33.3% versus 18.5%), and SF-6D score (21.3% v

16 0.3 to 5.4; P = .08), no change in the SF-36 MCS score at 3 weeks (mean, 2.2; 95% CI, -0.4 to 4.8; P

17 7; P = .02) greater improvement in the SF-36 MCS score at 52 weeks.

18 nts in mental HRQL (all P < or = .02) (SF-36 MCS: Delta, 3.2 points; 95% confidence interval [CI], 0.

19 kely to benefit from the intervention (SF-36 MCS: Delta, 5.7 points; 95% CI, 2.2-9.2; P = .001).

20 n channel shifts (MCS) for LD and 162.8+/-41 MCS for DD) to time of transplant (T cell 68.2+/-58 MCS

21 DD) to time of transplant (T cell 68.2+/-58 MCS for LD [P<0.00006] and 125+/-49 for DD [P=0.05]), re

22 We searched 3,812 MCS patients from June 2006 through March 2011 in the IN

23 sustained virological response patients all MCS symptoms persistently disappeared (36 patients, 57%)

24 ls, leading to reduced infection rates among MCS recipients.

25 PCS was 43.5 versus 37.0 and MCS was 54.2 versus 52.0 among women with adherence scor

26 lower PCS scores (48.0 v 52.8; P < .001) and MCS scores (45.8 v 48.9; P = .002) when compared with po

27 lation mean for both PCS (45.6 +/- 10.4) and MCS (47.3 +/- 11.5) but increased to just above the nati

28 of follow-up for both PCS (50.7 +/- 9.6) and MCS (50.1 +/- 10.0).

29 itivity and specificity in the benchmark and MCS population, PCI offers a reliable, independently val

30 e of overall complications between FLACS and MCS (RR, 2.15; 95% CI, 0.74 to 6.23; P = 0.16); however,

31 Studies containing both FLACS and MCS arms that reported on relevant efficacy and/or safet

32 lly significant difference between FLACS and MCS for total surgery time (WMD, 1.25; 95% CI, -0.08 to

33 icant differences detected between FLACS and MCS in terms of patient-important visual and refractive

34 nt difference was detected between FLACS and MCS in uncorrected distance visual acuity (WMD, -0.02; 9

35 grading Mycobacterium (strains JLS, KMS, and MCS, and M. gilvum PYR-GCK), presenting evidence for pas

36 tion, and wound infections) in HTx, LTx, and MCS device recipients was reported at 2.2%, 5.5%, and 10

37 mendation was associated with higher PCS and MCS after adjusting for demographic and medical confound

38 oriasis severity was associated with PCS and MCS after adjusting for variables, although the strength

39 significantly associated with better PCS and MCS after adjustment for age, education, marital status,

40 y was to determine whether the SF-12 PCS and MCS are associated with psoriasis severity and to compar

41 Changes in PCS and MCS from baseline were similar between the two randomiza

42 Regression analysis found the PCS and MCS from SF-12 to be major predictors of LVQOL, AVL-12,

43 e, disease classification, and SF-36 PCS and MCS scores (R(2) = 0.22, 0.23, and 0.66 for the SG, TTO,

44 Significant improvements in PCS and MCS scores from baseline to 24-month follow-up were obse

45 alyses revealed that improvements in PCS and MCS scores were primarily a function of being off-treatm

46 ation, whereas in the lower cluster, PCS and MCS scores were significantly lower than in the general

47 The PCS and MCS were able to differentiate patients with more breath

48 When the PCS and MCS were evaluated, the PCS, but not the MCS, was found

49 RQOL improvements (measured by SF-36 PCS and MCS, and ASQoL scores) and ASAS clinical responses (P <

50 S and esophageal involvement reduced PCS and MCS.

51 identified for the time profiles of PCS and MCS.

52 obacteriaceae in solid organ transplants and MCS device recipients are essential in successful patien

53 understanding of the linkage between EMs and MCSs.

54 Of particular interest are MCSs within noncoding regions previously shown to contai

55 as clinical remission at week 10, defined as MCS of 2 or less (with no individual subscore of >1), an

56 ng antiviral (DAA) therapy in HCV-associated MCS (HCV-MCS) is largely unknown.

57 At MCS, specific proteins tether the organelles in close pr

58 ing domains found exclusively in proteins at MCS.

59 with the highest inhibition was found to be MCS, with an IC50 value of 0.29muM.

60 t strategy for TBI patients when considering MCS is unclear.

61 We fed mice custom MCS and MCD formulas containing 4 different carbohydrate

62 atients, 57%); in only two (3%) did definite MCS persist.

63 nslational control offered by these designed MCSs is paramount to obtaining high titers of heterologo

64 ulted in a sensitivity of 94.7% in detecting MCS and allowed the identification of a number of unresp

65 port proteins (Ltc/Lam) localized at diverse MCSs.

66 In such patients, durable MCS may offer an important chance for life prolongation.

67 for a well-tolerated, durable and effective MCS option in patients with refractory heart failure.

68 ting a mutant strain in which prpC (encoding MCS) and prpD (encoding MCD) were deleted.

69 arose once within the intronic RET enhancer MCS+9.7.

70 v2.1 localization and the induction of PM:ER MCS are accompanied by increased mitotic Kv2.1 phosphory

71 The M phase clustering of Kv2.1 at PM:ER MCS in COS-1 cells requires the same C-terminal targetin

72 ession of Kv2.1 induces more exuberant PM:ER MCS in neurons and in certain heterologous cell types.

73 smic reticulum membrane contact sites (PM:ER MCS), and overexpression of Kv2.1 induces more exuberant

74 fic clusters of Kv2.1 are localized to PM:ER MCS, and M phase clustering of Kv2.1 induces more extens

75 tering of Kv2.1 induces more extensive PM:ER MCS.

76 In comparison with an existing MCS tool, fmcsR shows better time performance over a wid

77 CS cells developed increased climbing fiber (MCS) or parallel fiber (ZCS) input during visual stimula

78 erant search method for identifying flexible MCSs (FMCSs) containing a user-definable number of atom

79 is article, a new backtracking algorithm for MCS is proposed and compared to global similarity measur

80 n previous years, the primary indication for MCS therapy supported bridge to transplantation.

81 female (72% vs. 24% vs. 13%, p = 0.001), had MCS more often implanted as destination therapy (33% vs.

82 ects donated platelets using the Haemonetics MCS+, COBE Spectra (Spectra), or Trima Accel (Trima) sys

83 p and both the MC-HCV (P = 0.009) and MC-HCV+MCS-HCV (P = 0.014) groups.

84 HCV-MCS was defined by circulating cryoglobulin associated w

85 tes for sofosbuvir-based DAA regimens in HCV-MCS were 83%, significantly higher than historical contr

86 ral (DAA) therapy in HCV-associated MCS (HCV-MCS) is largely unknown.

87 ors studied case series of patients with HCV-MCS who were treated with sofosbuvir-based regimens and

88 SF-12 mental health (MCS-12) scores decreased until 18 months but improved fr

89 y recommendations was associated with higher MCS only.

90 In addition to maintaining cell homeostasis, MCS formation recently emerged as a mechanism by which i

91 However, MCSs impose a necessary distance between promoter elemen

92 h time maintained above 75% of baseline (T(i)MCS and T(i)sym) and mean improvement (microMCS and micr

93 NIV improved T(i)MCS, T(i)sym, microMCS, microsym, and survival in all pa

94 ed translation inhibition to design improved MCSs for significantly higher and more consistent protei

95 In MCS, intracranial, intrathoracic and intra-abdominal com

96 e 1980s (e.g., 0.229 [95% CI 0.219-0.240] in MCS males; 0.071 [0.065-0.078] in NSHD males).

97 There were 6070 families in GUI and 7768 in MCS.

98 SI, there was a 1.1 +/- 1.3 unit decrease in MCS (P=0.100) and a 2.4 +/- 1.3 unit decrease in PCS (P<

99 ns in infection prevention and management in MCS patients.

100 ing the existence of redundant mechanisms in MCS formation.

101 ious state (MCS); the second had remained in MCS for 6 years.

102 responsiveness in a patient who remained in MCS for 6 yr following traumatic brain injury before the

103 The clinical-immunological response in MCS-HCV correlated with the virological one.

104 lowing R peak was significantly shortened in MCS when the auditory rule was violated.

105 e variance in PCS and 10% of the variance in MCS.

106 e variance in PCS and 56% of the variance in MCS; demographic and clinical variables explained up to

107 d not suppress the formation of ER-inclusion MCS, suggesting the existence of redundant mechanisms in

108 contribute to the formation of ER-inclusion MCS.

109 , relative humidity, and VWS, which increase MCSs' lifetime by 3-30 h, 3-27 h, and 3-30 h per 1sigma

110 We find that intense MCS frequency is only weakly related to the multidecadal

111 ncrease in the frequency of the most intense MCSs.

112 th anxiety, it explained 24% of interpatient MCS variability.

113 y and particularly on days with long-lasting MCSs, accounts for the changes in the precipitation prod

114 ased frequency and intensity of long-lasting MCSs.

115 nctional homology to the mammalian alpha-LCR MCS-R2 region was confirmed by robust and specific repor

116 With learning, MCS and ZCS cells developed increased climbing fiber (MC

117 ity and duration of lcSSc were linked to low MCS.

118 nce was associated with higher PCS but lower MCS, whereas adherence to the dietary recommendations wa

119 aneously but show no (UWS) or only marginal (MCS) signs of awareness.

120 no significant difference in change of mean MCS scores (intervention group mean at baseline, 49.1; a

121 tifs may be a common feature of VAP-mediated MCS formation.

122 ts were the SF-36 physical (PCS) and mental (MCS) component summaries.

123 mes included mean physical (PCS) and mental (MCS) health QOL composite scores and reporting long-term

124 This study demonstrates that monitoring MCS pressure anomalies in the interior of the U.S. provi

125 PCS but not MCS scores were worse for AYA patients diagnosed with ca

126 The probability of IABP and O-MCS use varied across hospitals, and the use of O-MCS wa

127 tal-level variation in the use of IABP and O-MCS were evaluated.

128 ly, and 2747 (3.6%) received both IABP and O-MCS.

129 over time without a concurrent increase in O-MCS use.

130 The probability of O-MCS use was <5% for half of hospitals and >20% in less t

131 e of 0.3% per quarter, whereas the rate of O-MCS use was unchanged over the study period.

132 se varied across hospitals, and the use of O-MCS was clustered at a small number of hospitals.

133 ) received IABP only, 2711 (3.5%) received O-MCS only, and 2747 (3.6%) received both IABP and O-MCS.

134 c shock received an IABP and 6.7% received O-MCS.

135 and other mechanical circulatory support (O-MCS) devices in patients undergoing percutaneous coronar

136 Despite improving outcomes, application of MCS in critical illness is associated with excessive mor

137 embrane protein VAP is a common component of MCS involved in both tethering and lipid transfer by bin

138 ms involved in the antinociceptive effect of MCS are not clearly understood.

139 s for patients with TBI given the effects of MCS.

140 d to persistent resolution or improvement of MCS, strongly suggesting the need for a next generation

141 he perioperative and long-term management of MCS patients.

142 nrichment of active structures at the top of MCS-based similarity search results.

143 Yet, there are no data to support the use of MCS in this increasingly prevalent group of patients.

144 important observations for early warnings of MCS-generated tsunamis.

145 in dealing with anticoagulation, weaning of MCS, achieving optimal device settings, and end-of-life

146 te the first performance-based assessment of MCSs in yeast, showing that commonly used MCSs can induc

147 Despite the additional computation of MCSs, AILP achieved significant time reduction in comput

148 e able to minimize the inhibitory effects of MCSs with the yeast TEF, CYC and GPD promoters.

149 a dramatic increase in our understanding of MCSs, revealing the critical roles they play in intracel

150 explains up to 24% of the total variance of MCSs' lifetime during the decay phase.

151 xplain up to 20-22% of the total variance of MCSs' lifetime over equatorial South America compared wi

152 n Ocean can explain 20% of total variance of MCSs' lifetime over South Asia because such MCSs form an

153 y searching, clustering and visualization of MCSs.

154 The effect of aerosols on MCSs' lifetime varies between different continents.

155 osed as in the state of either UWS (n=53) or MCS (n=39).

156 er cortical information processing in UWS or MCS in a large group of patients using electroencephalog

157 f local regularities in either the VS/UWS or MCS patients.

158 likelihood of recovery of patients in UWS or MCS.

159 ated with MCS have survival similar to other MCS patients despite more frequent need for right ventri

160 Several other MCSs represent candidate GDF6 regulatory elements; many

161 ignificant difference in favor of FLACS over MCS for effective phacoemulsification time (WMD, -3.03;

162 Among women in the QOL analysis, mean PCS, MCS, and CES-D scores worsened modestly over the study's

163 Mean PCS, MCS, and PHQ-9 scores were relatively stable over a medi

164 al and mental component summary scores (PCS, MCS) from the Medical Outcomes Study Short Form-36 Healt

165 The median scores for the PCS, MCS, and HAQ DI were 36.9, 45.5, and 0.9, respectively.

166 using physical/mental component summary (PCS/MCS) and six domain scores of the Medical Outcomes Study

167 limit them to the identification of perfect MCSs.

168 Post-MCS, early improvement in renal function is common but s

169 the mechanistic basis for these complex post-MCS changes in renal function and their associated survi

170 Early post-MCS, eGFR improved substantially (median improvement, 48

171 f this analysis were to describe serial post-MCS changes in estimated glomerular filtration rate (eGF

172 by 1 year, eGFR was only 6.7% above the pre-MCS value (P<0.001).

173 remarkably rapid intensification of Sahelian MCSs since the 1980s sheds new light on the response of

174 rming intensifies convection within Sahelian MCSs through increased wind shear and changes to the Sah

175 ss-linked with divalent cationic CaCl2 salt (MCS), and the third group consisted of control microcaps

176 52.8; P < .001) and mental component scale (MCS) scores (42.9 v 48.9; P < .001) when compared with p

177 and a median mental health composite scale (MCS) of 52.5 (21-66), quality of life was not altered.

178 f 50, and the median mental component score (MCS) was 52.2 (95% CI 48.5, 54.3).

179 score (PCS) and the mental component score (MCS).

180 tients (aged 18-75 years; Mayo Clinic Score [MCS] of 5 of higher [or >/=6 in USA]; and disease extend

181 t scores and mental health component scores (MCS) between groups at baseline on the Medical Outcomes

182 or the mental and physical composite scores (MCS and PCS) and for the 8 dimensions of the short-form

183 2 kb of microsatellite containing sequences (MCS) revealed a high incidence of cryptic repetitive DNA

184 series of multispecies conserved sequences (MCSs).

185 on deletion sets represent minimal cut sets (MCSs).

186 Unique multicore-shell (MCS) structure of the electrospun composite fibers was o

187 nt (T cell 183.5+/-98.4 mean channel shifts (MCS) for LD and 162.8+/-41 MCS for DD) to time of transp

188 cell FXMs less than 300 mean channel shifts (MCS).

189 sults were expressed as mean channel shifts (MCS).

190 We used Monte Carlo simulation (MCS) methods with a previously published population-phar

191 Monte Carlo simulations (MCS) were performed for models with one susceptible bact

192 Membrane contact sites (MCS) are zones of contact between the membranes of two o

193 Membrane contact sites (MCS) between organelles are proposed as nexuses for the

194 Membrane contact sites (MCSs) function to facilitate the formation of membrane d

195 often referred to as membrane contact sites (MCSs), mostly form between the endoplasmic reticulum and

196 ER)-vacuole/lysosome membrane contact sites (MCSs).

197 Multicloning sites (MCSs) in standard expression vectors are widely used and

198 ave developed a modified cyclodextrin solid (MCS) medium using the selective antibiotic cefdinir.

199 mpressive stress on multicellular spheroids (MCSs) used as a tumor model system.

200 as multiple, single, or zero complex spike (MCS, SCS, ZCS) cells.

201 gum (LBG), modified corn and rice starches (MCS, MRS)) to an infant formula on both in vitro mineral

202 tate (VS/UWS), 36 minimally-conscious state (MCS) and 11 severe disability.

203 rentiation of the minimally conscious state (MCS) and the unresponsive wakefulness syndrome (UWS) is

204 ve state) or in a minimally conscious state (MCS) open their eyes spontaneously but show no (UWS) or

205 n patients in the minimally conscious state (MCS), a condition that is characterized by intermittent

206 ate (VS), 27 in a minimally conscious state (MCS), and 6 emerging from a minimally conscious state (E

207 ter 19 years in a minimally conscious state (MCS); the second had remained in MCS for 6 years.

208 /UWS; n = 70) and minimally conscious state (MCS; n = 57) were presented with the local-global audito

209 patients (38 in a minimally conscious state [MCS] and 43 in a vegetative state [VS]).

210 me, VS/UWS, and 7 minimally conscious state, MCS) and compared these properties with those of healthy

211 Motor cortex stimulation (MCS) has been used clinically as a tool for the control

212 often substantially larger than their strict MCS counterparts.

213 tion to thin membrane connective structures (MCS)/nanotubes that communicate effector and susceptible

214 , and the 2000-2002 Millennium Cohort Study (MCS) to analyze how this association has changed over ti

215 PAC; 7-18), or 2001 Millennium Cohort Study (MCS; 3-11).

216 [GUI]) and the UK (Millennium Cohort Study [MCS]).

217 The maximum common substructure (MCS) approach provides a more promising and flexible alt

218 and graph-based maximum common substructure (MCS) methods.

219 MCSs' lifetime over South Asia because such MCSs form and develop over the ocean.

220 maries (PCS) and mental component summaries (MCS) and the EQ-5D (with a visual analog scale [VAS])-we

221 the short form 36 mental component summary (MCS) and the sleep apnoea quality-of-life index symptoms

222 ischarge using the Mental Component Summary (MCS) of the 36-Item Short-Form Health Survey (SF-36 [ran

223 Summary (PCS) and Mental Component Summary (MCS) of the Veterans RAND 12-Item Health Survey, the Pat

224 summary (PCS) and mental component summary (MCS) scales, functional questionnaires, and physiologic

225 scales, and SF-36 mental component summary (MCS) score were statistically significant for CYC versus

226 Summary (PCS) and Mental Component Summary (MCS) scores (0-100 scale; higher scores better).

227 observed in SF-36 Mental Component Summary (MCS) scores.

228 ; range 0-100) and Mental Component Summary (MCS; range 0-100), the Center for Epidemiologic Studies

229 ent summary [PCS], mental component summary [MCS]) with these outcomes.

230 Maternal choline supplementation (MCS) induces lifelong cognitive benefits in the Ts65Dn m

231 compared to methionine-choline-supplemented (MCS) diet feeding evidenced by liver steatosis, increase

232 t (LTx), and mechanical circulatory support (MCS) device recipients at a large transplant center.

233 revention in mechanical circulatory support (MCS) device recipients.

234 Mechanical Circulatory Support (MCS) devices are 'life-sustaining devices' placed as a b

235 f short-term mechanical circulatory support (MCS) devices, the state of their present use has not bee

236 nction after mechanical circulatory support (MCS) has yet to be characterized in a large multicenter

237 e of durable mechanical circulatory support (MCS) in patients with chemotherapy-induced cardiomyopath

238 hat utilized mechanical circulatory support (MCS) in the treatment of heart failure and to elaborate

239 rstanding of mechanical circulatory support (MCS) increases, the management of these devices has beco

240 with ongoing mechanical circulatory support (MCS) is expanding significantly.

241 can provide mechanical circulatory support (MCS) to patients with acute hemodynamic compromise and c

242 (FLACS) relative to manual cataract surgery (MCS).

243 Miles-Carpenter syndrome (MCS) was described in 1991 as an XLID syndrome with fing

244 physiology of multiple compartment syndrome (MCS) and current treatment considerations for patients w

245 on cause of mixed cryoglobulinemia syndrome (MCS).

246 onging to the following groups: MC syndrome (MCS)-HCV (121 patients with symptomatic MC), MC-HCV (132

247 sesses homologues of methylcitrate synthase (MCS) and methylcitrate dehydratase (MCD) but not 2-methy

248 well-developed mesoscale convective system (MCS) was studied using both satellite observations and c

249 ltiphase flows inside microcapillay systems (MCS).

250 by atmospheric mesoscale convective systems (MCSs) propagating from inland to offshore.

251 e dominated by mesoscale convective systems (MCSs), the largest type of convective storm, with increa

252 intense storms-mesoscale convective systems (MCSs)-poses a particular challenge, because they organiz

253 he lifetime of mesoscale convective systems (MCSs).

254 yzed all adult patients receiving short-term MCS in the United States from 2004 to 2011 by using the

255 Use of short-term MCS in the United States has increased rapidly, whereas

256 , use of percutaneous devices for short-term MCS increased by 1,511% compared with a 101% increase in

257 .50; 95% CI: 2.20 to 5.57) before short-term MCS were among the most significant predictors of mortal

258 ng hospital costs associated with short-term MCS.

259 ices, survival rates, and cost of short-term MCS.

260 These data demonstrate that MCS exerts lasting effects on offspring choline metaboli

261 onducted a study to test the hypothesis that MCS alters choline metabolism in adult Ts65Dn offspring.

262 nalysis of trends across Africa reveals that MCS intensification is limited to a narrow band south of

263 The test results show that MCS complements the well-known atom pair descriptor-base

264 Our results show that MCSs' lifetime increases by 3-24 h when vertical wind sh

265 The MCS and DSA levels for patients with AMR were significan

266 at enables researchers to easily combine the MCS-based and traditional similarity measures with moder

267 mulate a natural mutation, which deletes the MCS-R2 alpha-globin enhancer and causes alpha-thalassemi

268 Care for the MCS patient provided in a multidisciplinary team approac

269 d physical components of general health (the MCS and PCS of SF-12), well-being (WHO-5), use of magnif

270 tor machines (SVMs) are used to test how the MCS-based similarity measure and the basis compound vect

271 as more than halved for children born in the MCS cohort (-0.14, 95% CI: -0.22, -0.06).

272 six-item psychological distress scale in the MCS cohort when children were 7 years old.

273 t p=0.435 in the GUI cohort and 0.470 in the MCS cohort).

274 0.18 SMFQ points (0.01-0.36; p=0.041) in the MCS cohort.

275 rs in the GUI cohort and age 14 years in the MCS cohort.

276 hift of the cardiac cycle exclusively in the MCS group.

277 hat further recovery in some patients in the MCS is limited by chronic underactivation of potentially

278 Moreover, the MCS membrane (at ~200 degrees C), as a lithium ion batte

279 and MCS were evaluated, the PCS, but not the MCS, was found to be associated with damage but not with

280 n those in the upper and lower ranges of the MCS patients, and lowest in VS patients.

281 compressive stress causes a reduction of the MCS volume, linked to a reduction of the cell volume in

282 uction of the cell volume in the core of the MCS.

283 ibuted remarkable thermal stabilities to the MCS membrane.

284 consistent with that of the variation of the MCSs' ice water content (IWC) with aerosols, which accou

285 nd 34%, respectively, of the variance of the MCSs' lifetime.

286 d the pressure anomalies associated with the MCSs.

287 activity was decreased in VS/UWS compared to MCS, and correlated with clinical score.

288 t of VS/UWS patients, two of whom evolved to MCS.

289 especially for emergent decisions related to MCS devices.

290 on of prostaglandins after FLACS relative to MCS (WMD, 198.34; 95% CI, 129.99-266.69; P < 0.001).

291 ACS is more efficacious and safe relative to MCS.

292 pproach using Vermilion-AttB-Loxp-Intron-UAS-MCS (VALIUM), a vector that contains vermilion as a sele

293 tient or while managing a patient undergoing MCS.

294 decipher the molecular mechanisms underlying MCS formation.

295 of MCSs in yeast, showing that commonly used MCSs can induce dramatic reductions in protein expressio

296 d Nvj3 in this study) localize to ER-vacuole MCSs independently of established tether Nvj1.

297 re significantly more common in FLACS versus MCS (RR, 3.73; 95% CI, 1.50-9.25; P = 0.005).

298 CCMP patients treated with MCS have survival similar to other MCS patients despite

299 Patient are living longer with MCSs for bridge to transplant (BTT) and destination ther

300 variant disrupts a SOX10 binding site within MCS+9.7 that compromises RET transactivation.